Wednesday, March 20, 2019

Sexual Wellness Market Size, Share, Trends Analysis & Competition through 2023

Market Highlights

The global sexual wellness market anticipated to have held a market value of USD 21.26 billion in the year 2017 and is expected to grow at a CAGR of 9.2% during the forecast period. Sexual health is experience of physical, psychological and social cultural related to sexuality. The products such as, sex toys, condom & contraceptives, sexual enhancement supplements, lubricants, ointments view as a sexual wellness product that provides enjoyment in sexual experience and security.

Increasing global prevalence of Sexually Transmitted Diseases (STDs), increase in awareness regarding sexual health items, and development of e-commerce business are expected to drive the growth of market. According to the Centers for Disease Control and Prevention (CDC), in 2017 around 1,708,569 were suffer with Chlamydia trachomatis infection in US. Similarly, in 2017, around 555,608 were suffer with gonorrhea and 30,644 were suffer with Syphilis in US. Moreover, According to World Health Organization (WHO), every year estimated around 357 million new people suffer with sexually transmitted infections (STIs). Furthermore, according to The Joint United Nations Programme on HIV/AIDS (UNAIDS), in 2017 estimated that 5.2 million suffer with HIV in Asia-Pacific. On other hand, side effects due to toxic ingredients in products and product recalls can restrain the market growth over the assessment period.

Get Free Sample of This Report @ https://www.marketresearchfuture.com/sample_request/7328
Regional Analysis
Geographically, the Americas is expected to dominate the global sexual wellness market owing to the presence of well-established players, increasing prevalence of Sexually Transmitted Diseases (STDs), increase in awareness regarding sexual health items, and developed e-commerce business. Europe is expected to hold the second largest position in the global sexual wellness market. Asia-Pacific is expected to be the fastest growing market owing to the increasing awareness about sexual wellness products and supportive sex education programs. Furthermore, the Middle East and Africa region is expected to account for the least market share in the global sexual wellness market.

Segmentation
The global sexual wellness market has been segmented into product and distribution channels.
Based on product, sexual wellness market is segmented into sex toys, condom & contraceptives, sexual enhancement supplements, lubricants, ointments, and others. The sex toys segment is expected to account for the largest share segment of the market in 2017.

Based on distribution channels, sexual wellness market is segmented into retail and online platforms. The retail segment is expected to account for the largest share segment of the market in 2017. Retail segment further sub segmented into drug stores, specialty stores, and others.


Key Players
Some of the prominent players in the global sexual wellness market are LELO (Sweden), Doc Johnson (US), Church & Dwight Co., Inc. (US), Ansell Ltd. (Australia), Reckitt Benckiser Group plc (UK), LifeStyles Healthcare (Australia), Karex Berhad (Malaysia), Veru Inc. (US), Mankind Pharma (India), and BioFilm IP LLC (US).
Posted by at No comments:
Labels: ,

Healthcare CRM Market to Grow at CAGR of 13.8% through 2023

The global healthcare CRM market held a market value of USD 7.9 billion in 2017 and is projected to grow at a CAGR of 13.8% over the forecast period. Customer relationship management (CRM) is a tool used as an approach for managing interactions with patients and helps in managing, coordinating, and automating the business processes. CRM analyzes and segments consumer and patient populations which ultimately aids in measuring the success of engagement tactics using configurable reporting. The benefits of CRM solutions, such as the easy arrangement of customer data and interactions and the simplification of business processes (customer service and support, marketing, sales, and digital marketing) is expected to boost the growth of the market over the forecast period. Additionally, increasing emphasis on patient engagement and rising demand for structured data and automation in healthcare organization are fueling the growth of this market. As per the data by HIMSS Mobile Technology Survey (2015) stated that 93% of physicians believe that mHealth apps can improve patient’s health and 40% of physicians believe mHealth technologies can decrease the number of visits to doctors’ offices. However, high cost and complexity of CRM and concerns regarding data security may high cost and complexity of CRM and concerns about data security may hinder the market growth during the assessment period.


Regional Analysis
On regional basis, the Americas is anticipated to dominate the global healthcare CRM market owing to the growing clinical R&D budgets by both governments to encourage the adoption of healthcare IT and electronic health record (EHR). According to The Office of the National Coordinator for Health Information Technology, a division of the U.S. Department of Health and Human Services in 2015, 84% of hospitals adopted at least a Basic EHR system in US. Europe is expected to hold the second largest position in the global healthcare CRM market owing to the excellent network and IT development in the region. Moreover, growing effort of CRM providers on developing and commercializing Artificial Intelligence (AI) and analytics-powered innovative CRM solutions, and the growing number of Accountable Care Organizations (ACOs) is driving this market in European countries. The Asia-Pacific region is anticipated to be fastest growing region is due to improving quality of healthcare systems, rising medical tourism market and increasing government initiatives. According to a study published by the Indian Journal of Science and Technology in 2016, the EHR adoption in China was projected to be about 96%. The Middle East & Africa has the least share of the global healthcare CRM market. Moreover, the major market share of the region is expected to be held by the Middle East region owing to the increasing demand for the novel technologies in healthcare sector.

Segmentation
The global healthcare CRM market has been segmented into Component, Deployment model, Functionality and End User.
By Component, the market has been segmented into Services and Software. On the basis of Deployment model, the global healthcare CRM market has been segmented into On-Premise Model and Web/Cloud-Based Model. The Web/Cloud-Based Model is further segmented into Public Cloud, Private Cloud and Hybrid Cloud. The global healthcare CRM market, by Functionality, has been segmented into Customer Service and Support, Marketing, Sales, Digital Marketing and others. On the basis of End User, has been segmented into Healthcare Providers, Life science Industry and Healthcare Payers.


Key Players
Some of the prominent players in the global healthcare CRM market are Saleforce.Com, Inc., Oracle, Microsoft, IBM, SAP SE, Influence Health, Inc., Accenture, Healthgrades, Infor, Inc., Amdocs Ltd., Anthelio Healthcare Solutions, AllScripts Healthcare Solutions Inc., NetSuite.
Posted by at No comments:
Labels: , , , , ,

Lupus Market is Expected To Grow At A CAGR Of 11.2% By 2023

Lupus is a chronic autoimmune disease which occurs when the immune system attacks the healthy cells and tissues of the body, thereby causing inflammation, pain, swelling, and damage throughout the body. Many people have an inherit tendency towards developing or attaining lupus, which can be triggered due to certain drugs, infections, or even sunlight. The prevalence of this condition has prompted Market Research Future (MRFR) to take notice and study the global Lupus market. As of 2017, the market valuation of Lupus stood at USD 1.48 billion. However, as per the latest studies, the global lupus market is projected to grow significantly during the forecast period with a CAGR of 11.2%.

Various factors such as the growing prevalence of lupus diseases, increasing R&D activities, and continuing medical advancements for the treatment of systemic lupus erythematosus are all identified as key factors driving the growth of the market. Also, the market involves a number of noteworthy companies that are involved in the development of new products and product launches. However, irrespective of the market drivers, constraints such as strict government regulation and rising prices of lupus drugs can severely hamper its market growth during the review period.


Market Segmentation
The lupus market segmentation is done on the basis of treatment, end-user, and types.
By treatment, the market includes antimalarial drugs, corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), biologics, immunosuppressants, and others.
By end-user, the market divides into diagnostic laboratories, hospitals and clinics, and others.
Lastly, by type, the market comprises cutaneous lupus erythematosus, systemic lupus erythematosus, neonatal lupus, and drug-induced lupus erythematosus. The lupus erythematosus market segment is projected to hold the largest market percentage due to the increasing prevalence of such diseases and the increasing drug development over the years.

Regional Analysis
The global lupus market is geographically segmented into the following regions: Americas, Asia Pacific, Europe, and the Middle East & Africa.

The Americas is anticipated to be the most dominant regional market due to a number of factors. This includes the growing prevalence of lupus diseases, rising demand for better treatment options, favorable government initiatives, and the availability of reimbursement. In addition to these, the established healthcare infrastructure facility coupled with the accessibility to biologics are also expected to propel the market growth of this region.
The European market is believed to hold the second-largest market position following the Americas. The growth of the market herein is attributed to the expanding R&D activities and widespread prevalence of lupus diseases.
The Asia-Pacific region is expected to be the fastest-growing regional market. This can be attributed to the growing healthcare sector, the rising incidences of lupus diseases, and increasing regional expansion by prominent market players. The Middle East & Africa region holds the least market share among all the mentioned regions.


Competitive Landscape
The global lupus market holds a number of noteworthy players, including Merck KGaA, Cadila Healthcare, Mylan N.V., F. Hoffmann-La Roche AG, Aurinia Pharmaceuticals, Inc., GlaxoSmithKline PLC, Eli Lily and Company, Pfizer, Inc., Bristol-Myers Squibb Company, Lycera Corporation, and Sanofi.
Dec 11th, 2018, Neovacs, a pioneer in the field of active immune therapy for treating autoimmune diseases, announced the continuation of its partnership with Centurion Pharma in Lupus (SLE). This is based on the study results of the Phase IIb trial with IFNalpha Kinoid.
Posted by at No comments:
Labels: , , ,

Infertility Market to Register an Exponential CAGR of 4.6% By 2023

Market Scenario:
The most common causes of infertility include deficiencies in semen or egg production such as poor quality and sperm motility, lower hormonal levels, abnormal ejaculation and even psychological conditions. As per Market Research Future (MRFR)’s analysis, the market for infertility stood at 11.2 billion in 2016, and is projected to expand at a CAGR of 4.6 % during the forecast period ending 2023.

Market Dynamics:
Rise In Risk Factors Is The Prime Reason For Market Growth
The increase in risk factors for the global infertility market is sedentary lifestyles, increasing age at marriage, substance abuse, environmental factors, genetic abnormalities, stress, obesity, prostate cancer, varicocele, and others. Smoking, alcohol, anabolic steroid use, and illicit drug use is positively correlated to the growth of infertility. Cancer treatment such as chemotherapy, radiation, also affects fertility. Late marriage and hormonal disorders are other causes associated with infertility. Women infertility is caused by Polycystic ovary syndrome (PCOS), Functional hypothalamic amenorrhea, pelvic infection, ruptured appendicitis, gonorrhea or chlamydia, endometriosis, or abdominal surgery.


Growth In Awareness and Growing Number of fertility Clinics Is Driving A Large Demand
There has been a keen awareness regarding infertility with concurrent development of fertility clinics. The advent of assisted reproductive techniques has resulted in a significant adoption of these services by the market.
Poor Efficacy of Treatment and High Cost Sssociated May Hamper Market’s Growth
The prime market constraints include the high cost of the procedure, side effects of the drug therapy and social taboos for Infertility treatment and others.

Segments:
To gauge an accurate understanding of the market potentiality, the report is segmented by sex, diagnosis, drugs, techniques, and regions.
Based on the sex, the market is bifurcated as males, females and unexplained.
Based on the diagnosis, the market is bifurcated as men diagnostic tests (semen analysis, genetic testing, testicular biopsy, and other), women diagnostic tests (hysteroscopy, laparoscopy, ovulation testing, hysterosalpingography and others), and general diagnostic tests (genetic testing, hormone testing, microscopic analysis, imaging, and others)
Based on drugs, the market is segmented into clomiphene citrate, letrozole, serophene, hormone treatment and others.
Based on techniques, the market is segmented by assisted reproductive technology (ART), intrauterine insemination, and surgery. The surgery segment is further sub-segmented by laparoscopic or hysteroscopic surgery, tubal surgeries and others. Based on geography, the market is charted according to North America, Europe, Asia Pacific, Middle East, and Africa.


Regional analysis
The US accounts for the maximum market share of the global infertility market attributed to increasing pool of awareness, high income, and good reimbursement scenario. Europe led by Germany, France, and the U.K. is expected to be the second largest market. Advancing technologies within the Infertility treatment is driving the market and will see strategic growth over the next five years. The Asia Pacific, dominated by China, and India is projected to be the fastest growing market owing to a large population with unmet needs and also because the rate of male infertility is highest in South Asia.

Key players of Global Male Infertility Treatment Market:
Some of the key vendors operating and profiled in the report are Halotech DNA, SCSA Diagnostics, Inc., Andrology Solutions, Zydus Cadila Healthcare Ltd, Androvia LifeSciences, Aetna Inc., Bayer Healthcare, and EMD Serono, Inc.,
Posted by at No comments:
Labels: , , , , , ,

Multiplex Assays Market Analysis Revealing Key Drivers & Growth Trends through 2018 – 2023

Multiplex Assays Market – Overview
The uptick in demand for nanotechnology practices that can solve several genetic-related diseases has increased of late. The Multiplex Assays Market is anticipated to progress with a CAGR of 7.8% during the forecast period. The market for multiplex arrays is advancing due to the increased funding and research being diverted to the market. Increased awareness of the benefits of multiplex assays is fuelling the growth of the market over the forecast period. The multifactorial nature of several diseases and pathological conditions such as Alzheimer and cancer are motivating the development of the market significantly.

Segmental Analysis
The multiplex assay market is segmented on the basis of types, application, products and services, technology, and end-user. By products and services, the market is segmented into instrument, consumable, and software and services. Based on types, the market is segmented into nucleic acid, protein, and cell-based multiplex assay. On the basis of technology, the market is segmented into fluorescence detection, flow cytometry, luminescence, multiplex real-time PCR, and other technologies. On the basis of application, the market is segmented into clinical diagnostic, research and development, and other diseases. By end user, the market is segmented into hospital and research institutes, pharmaceutical and biotechnology companies, clinical laboratories, and other end-users.


Competitive Analysis
The availability of a good labor force along with assets is influencing to the general market advancement. The external factors that are motivating the market expansion which is dependent on the practices and the strategic roadmaps that are exploited by market players. The alteration in the quality of products and services is the chief factor is growing the market's output and swaying the trends that are fortifying their prominence in the market. The essential success factors and players’ inclinations are progressively improving by the strategies being used by market competitors. The market has brought in an innovative period of growth as the market is constantly in a state of mutability.  

The notable contenders shaping the market development over the forecast period are Illumina Inc, Bio Rad Laboratories Inc, Thermo Fisher Scientific Inc, Qiagen, Abcam plc, BD, Agilent Technologies, Meso Scale Diagnostics LLC, Merck Sharp & Dohme Corp, Quanterix, Bio-Techne, Randox Laboratories Ltd, and Seegene Inc.

Industry Updates:

Jun 2018 Laboratory Corporation of America announced of late that it has gotten US Food and Drug Administration consent for the UltraQual Multiplex PCR Assay for HIV-1, hepatitis C, HIV-2 and hepatitis B for the diagnosing of donated blood plasma.


Detailed Regional Analysis 
The North America region is accountable for the prime stake of the market due to robust R&D activities in this region. The US is a chief country in terms of biopharmaceutical research and development. The important factors that drive the development of the market in this region are the rise in-patient population, and the growing detection of Alzheimer disease, and a substantial rise in research and development activities of the pharmaceutical companies for the treatment of diseases such as cancer and Alzheimer. The Asia Pacific is anticipated to record the highest CAGR during the forecast period. Due to the increasing geriatric population, mounting prevalence of cataract, and growing prevalence of Alzheimer disease in this region. The European region is estimated to note a high CAGR during the forecast period owing to the increasing geriatric population.
Posted by at No comments:
Labels: ,

Mucormycosis Market Expected to Witness a Sustainable Growth over 2017 – 2023

Mucormycosis (zygomycosis) is a serious but rare fungal infection caused by a group of molds called mucormycetes. Moreover, inhaling fungal spores from the air can affect the lungs and sinuses, the fungus also invades the skin through wounds such as cut, scrape, burn, or other type of skin trauma. There are approximately 1.5 million different species of fungi on the earth, however, only around 300 are responsible for causing diseases and infections in humans. Fungal infection may affect anyone, but they are most common in people with weakened immune systems and can occur in nearly any part of the body. Risk factors for developing mucormycosis include uncontrolled diabetes, cancer, organ transplant, neutropenia, skin trauma such as cuts, scrapes, punctures, or burns.  
These infections need to be treated with prescribed antifungal medication, usually amphotericin B, posaconazole or isavuconazole. Amphotericin B, posaconazole, and isavuconazole are medications given intravenously. Furthermore, posaconazole and isavuconazole can also be administered orally. Often, mucormycosis requires surgery to remove the infected tissue.

The prognosis of mucormycosis is usually poor. It depends on various factors such as the overall health of the patient and ability to respond to treatments, the speed of diagnosis, and treatment provided. For instance, the mortality rate with rhinocerebral and GI mucormycosis is about 85% while the mortality rate for patients with other types of mucormycosis is about 50%. Patients who survive this infection often end up having disabilities such as blindness, limb loss, organ dysfunctions among others.


The market growth is mainly driven by increasing prevalence of fungal infections, availability of wide range of products, and rising incident of immunological diseases. Moreover, increasing awareness about fungal infection and increasing government support for research & development have fuelled the market growth. However, side effects of the treatment and presence of misbranded and spurious drugs may slow the growth of the market. There are a number of medicines available in the market for the treatment of fungal infections such as oral and intravenous medicines, creams, sprays, shampoos, solutions, and pessaries.

Rising incidence of immunological diseases and availability of a wide range of products has driven the growth of the global mucormycosis market. Furthermore, rising geriatric population, increasing government support, and increasing healthcare expenditure have fueled the growth of the market. However, side effects of the drugs and presence of misbranded drugs may hinder the growth of the market.

The global market for mucormycosis is expected to grow at a CAGR of approximately 7.3% during the forecast period, 2017-2023.

Key Players:
The Global Mucormycosis Market key players are Abbott Laboratories (U.S.), Biocon Limited (India),  Cadila Pharmaceuticals Limited (India), Novartis AG (Switerzland), F. Hoffman La Roche (Switerzland),   Merck Sharp and Dohme (U.S.), Mylan Labs (U.S.), Bristol Myers Squibb (U.S.),  Bayer AG (Germany), Lonza Group (Switerzland), Sanofi (France), Johnson & Johnson (U.S.), Pfizer Inc. (U.S.), Gilead Sciences (U.S.), and others

Segmentation:
The mucormycosis is segmented on the basis of species, diagnosis, treatment, and end-users.
On the basis of the species, the market is segmented into Rhizopus, Rhizomucor, Cunninghamella, Apophysomyces, Saksenaea, Lichtheimia (formerly Absidia), and Mucor, and others
On the basis of the diagnosis, the market is segmented into Computed Tomography (CT), Magnetic resonance imaging (MRI), tissue biopsy, and others.
On the basis of the treatment, the market is segmented into surgery, antifungal drugs, amphotericin B therapy, and others. The antifungal drugs is further categorized into posaconazole, isavuconazole, voriconazole, fluconazole, and flucytosine, and others.
On the basis of the end-user, the market is segmented into hospitals & clinics, medical institutes, research organization, and others.


Regional Analysis:                     
The Global Mucormycosis Market consists of countries namely the Americas, Europe, Asia Pacific, and the Middle East and Africa. The Americas dominate the global mucormycosis market owing to a well-developed healthcare sector and huge patient population for mucormycosis. Many antifungal drugs have lost their patients during the last few years such as Terbinafine products like Lamisil lost their patient in 2017. As there is limited oral preparation in the market, development and licensing of new drugs in the market is the huge opportunity for the development of the market during the forecasted period.

Europe is the second largest market for the global mucormycosis owing to the advancements in the technology of the surgical devices along with the rising occurrence of fungal infections among the patients. The European government introduced incentives to help simplify the improvement of anti-infective drugs and dropping the risk and cost of manufacturers. Some other factors driving the market include the growing percentage of diabetes mellitus population mainly in the developed countries of Europe. The average diabetes prevalence rate in Europe is 8.6% of the adult population.

Asia Pacific is the fastest growing region for antifungal treatment due to increasing prevalence of HIV, and huge untapped growth opportunities for the development of the market. Every year, approximately 7.1% of the Korean population receives treatment for fungal diseases. Therefore, further research is needed to understand and monitor the prevalence of mycoses to establish management policies to reduce the burden of fungal diseases.
Posted by at No comments:
Labels: ,

Tissue Engineering Market to Witness Heightened Revenue Growth in the Next Decade

The global tissue engineering market has been evaluated to grow at a steady pace and expected to reach at a high growth figures over the reviewing period. Tissue engineering is the use of combination of cells, engineering materials, and suitable biochemical factors to improve or replace biological functions in an efforts to repair damaged tissues and organs.

Neurology segment is one of the fastest growing owing to the increasing research & development and increasing cases of disorder related to nervous system. For instance, in March 2016, In the University of Alabama researchers found a reprogramming factor, which could increase the efficiency of Human induced Pluripotent Stem Cells (HiPSCs) and are generated without destroying the human embryo. These are major factor responsible for the growth of the market during forecast period.

The global tissue engineering market is expected to grow at a CAGR of 17.22% during the forecast period. Taste the market data and market information presented through more than 80 market data tables and figures spread over 110 pages of the project report. Avail the in-depth table of content TOC & market synopsis on “tissue engineering market research report–Global forecast till 2022.”


Major Players in Tissue Engineering Market
Some of the key players in the global market: Cook, Acelity, Baxter, DePuy Synthes Companies, Medtronic, Zimmer Inc., and Stryker

Regional Analysis
The global tissue engineering market consists of four regions: the Americas, Europe, Asia Pacific, and the Middle East & Africa. The Americas dominates the global market, particularly, North America due to growing developments in the field of regeneration surgeries, particularly stem cell research has created new opportunities for the global tissue engineering market. Additionally, continuous technological development methods and the presence of global market leaders contribute to the market growth.

Europe accounts for the second largest market due to availability of funds for research & development activities, and increasing government support for life sciences domain. Furthermore, industries are continuously focusing and upgrading the 3D technology and thereby offering better and enhanced organ and tissue printing methods.
Asia Pacific is the fastest growing market, whose growth is attributed to the improved economic conditions in healthcare domain, the government focus on research & development in healthcare sector. Moreover, increasing adoption of technological development in healthcare resulting in improvement of healthcare facilities expected to drive the market growth during the forecast period. The Middle East & Africa is expected witness limited growth due to limited access to the healthcare resources and lack of advanced medical facilities and less government encouragement in healthcare sector. 


Segmentation
Tissue engineering market has been segmented on the basis of materials, which comprises of biomimetic materials, nano-fibrous materials, composite materials, and nano-composite material. On the basis of applications, the market is segmented into orthopedics, musculoskeletal and spine, skin/integumentary, cancer, dental, cardiology, urology, neurology, cord blood & cell banking, GI & gynecology, and others. 
Posted by at No comments:
Labels: , , , , , , ,

Orphan Diseases Market to Create Lucrative Opportunities for Existing Companies as Well as New Players

Global Orphan Diseases Market – Forecast up to 2022 is a Research report published by Market Research Future where our report gives overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market and Also gives insights about factors affecting the market growth till 2022

 Global Orphan Diseases Market also known as rare disease is growing rapidly. It affects a very small percentage of the Global population. Most of the orphan diseases are genetic and is remains throughout the life of the patient. There are no exact number of diseases available but approximately there are about 7000 different rare diseases and disorders throughout the globe.

Global Orphan Diseases Market is expected to grow at the average CAGR of 24.9% constantly throughout this period 2015-2022. It is also expected that this market which was US$ 121.6 billion in 2015 will grow to US$ 576.9 billion by 2022. However due to lack of awareness, correct diagnosis, correct treatments and availability of healthcare facilities are inhibiting the growth of the Global Orphan Diseases Market.


Key Players for Global Orphan Diseases Market
Market Research Future (MRFR) recognizes the following companies as the key players in Orphan Diseases Market: There are plenty of large and small market players which operate in this market all over the globe. 
Some of the key players in this market are: Bristol-Myers Squibb Company (US), Novartis AG (Switzerland), CELGENE CORPORATION (US), F. Hoffmann-La Roche Ltd (Switzerland), Pfizer Inc. (US), Alexion (US), Sanofi (French), Vertex Pharmaceuticals Incorporated (US), GlaxoSmithKline plc. (UK), Merck & Co., Inc (US), AbbVie Inc. (US)

Regional Analysis for Global Orphan Diseases Market
Considering the Global scenario of this market, North American region is believed to be the largest market of the Global Orphan Diseases Market. Moreover the European market is also growing and is the second largest market for Global Orphan Diseases. On the other hand, Asia-Pacific’s orphan disease market is expected to grow at a significant rate during the forecasted period. Rest of the World is likely to have a limited but steady growth with respect to this market.


Segmentations for Global Orphan Diseases Market
Global orphan diseases market has been segmented on the basis of types of diseases which includes autoimmune disorders, genetic disorders, blood disorders, cancer, growth disorder, cardiovascular diseases, neurological disorders, respiratory disorders, digestive disorders, eye disorders and others. On the basis of treatment type it segmented into gene therapy, cell therapy, drug therapy and others. On the basis of end user the market is segmented into hospital and clinics, research laboratory and others.

The report of Global Orphan Diseases Market by Market Research Future comprises of extensive primary research along with the detail analysis of qualitative as well as quantitative aspects by various industry experts and key opinion leaders to gain a deeper insight of the market and industry performance. The report gives a clear picture of current market scenario which includes past and estimated future market size with respect to value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information about and strategies used by  top key players in the industry. The report also gives a broad study of different markets segments and regions.

Posted by at No comments:
Labels: , , , , , , ,

Migraine Market Size, Share, Trends Analysis & Competition through 2022

The global migraine market is presumed to demonstrate a healthy CAGR during the appraisal period (2017-2022) owing to the rising cigarette consumption across the globe. Migraine is referred to as a chronic neurologic disease which is characterized by severe recurrent headaches. One of the most prevalent and common disabling neurological conditions, migraine is characterized by migraine attacks. They differ from regular headaches which are non-migrainous and have a lower threshold that might cause neuronal hyperexcitability, including environmental or emotional challenges, sleep disturbances, diet, alcohol exposure, and hormonal changes. Migraine is associated with neurological indications like vomiting, nausea, and painful sensitivity to lights and sounds.

Drivers and Constraints Impacting the Market
The global migraine market is estimated to expand rapidly owing to the rising female population across the globe. With increasing healthcare expenditure, growing cigarette consumption, accelerating economic growth, and increasing prevalence of migraine and unmet needs, the global market for migraine is expected to flourish. Moreover, increasing awareness of migraine and its treatments coupled with development of migraine drugs are likely to stimulate the market growth. Also patient expirations are estimated to contribute to the market growth.
On the flip side, high cost, regulatory challenges, and lack of proper diagnosis are considered to dampen the market growth. Moreover, adverse effects of drugs and rising preferences of alternative therapies are presumed to hinder the market growth during the appraisal period.


Global Migraine Market: Segmental Analysis
The migraine market has been segmented on the basis of treatment types, types, drug class, and region.
By mode of type, the global migraine market has been segmented into chronic and episodic.
By mode of treatment type, the global migraine market has been segmented into abortive and preventive. Among these, the abortive treatment comprises therapeutic classes like ergot alkaloids, triptans, NSAIDs, and other non-specific drugs prescribed over-the-counter such as acetaminophen, aspirin, and ibuprofen. The preventive incorporates prescription of off-label and generic medications including beta blockers such as anti-epileptics and atenolol and propranolol like divalproex sodium and topiramate. In the current scenario, Amgen/Novartis’s Aimovig, Allergan’s Botox, and Teva’s Ajovy are the only drugs approved for migraine prevention.
By mode of drug class, the global migraine market has been segmented into ergots, triptans, and others.

Regional Insights
Geographically, migraine market span across Europe, North America, Asia Pacific, and the Middle East and Africa.
Among all the regions, the Asia Pacific region is considered to exhibit a significant growth rate owing to the rising focus of vendors on the emerging markets. The growth in this market is further attributed to the increasing demand for better healthcare facilities and improvements in the healthcare infrastructure. Moreover, this region represents remarkable opportunities for the investors and venture capitalists, as the developed markets are comparatively saturated. Such factors are likely to trigger the demand for migraine market during the appraisal period.

Industry Updates
November 15, 2018: Indianapolis-based Eli Lilly and Co. has recently applied for approval to the U.S. FDA regarding their new drug in order to treat migraine headaches. Lasmiditan will be used for the acute treatment of certain types of migraines in adults.


Competitive Dashboard
The prominent players operating the global market are Eisai Inc., Kowa Pharmaceuticals America, Merck, AstraZeneca plc, Eli Lilly and Company, Johnson & Johnson, Meda, Pfizer Inc., Impax Laboratories, OptiNose, Allergan, Luitpold Pharmaceuticals, Abbott Laboratories Inc., Klaria, and GlaxoSmithKline Plc.
Posted by at No comments:
Labels: , , , , , , ,

Vascular stents Market- Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 – 2023

Vascular stents are tiny tube like medical devices which are places into blood vessels or arteries to open the blockage in the vessels. Vascular stent is the valuable tool for the treatment of the different coronary diseases. Vascular stents are used to widen the narrow vessels so as to minimize the chances of heart attack and chest pain. This stents are prepared from variety of material. According to the WHO, approximately 18 million people died from cardiovascular diseases in 2014. Increasing number of people suffering from cardiovascular diseases is responsible for the driving the market. Additionally, globally 39% of adults aged 18 years and over were overweight whereas 13% were obese. Technological advances and increasing obese population is also contributed in the growth of the market. Other advantages like low risk of infection and short recovery time will also drive the market. However availability of alternative therapy and high cost of ventricular stents may restrain the growth of the market.

Global Vascular Stents Market   - Competitive Analysis
Boston Scientific Corporation (US), Abbott Laboratories (US), Medtronic, Plc (UK), Cook Medical (US), Biotronik se & co. kg (Germany), B. Braun Melsungen AG (Germany), Cordis (US), Lombard Medical Technologies (UK), Translumina GmbH (Germany), MicroPort Scientific Corporation (China), Terumo Corporation (Japan), Vascular Concepts (India), W.L. Gore & Associates (US), Meril Life Sciences Pvt. Ltd. (India) are some of the prominent players at the forefront of competition in the Global Vascular Stents Market and are profiled in MRFR Analysis. 
Many companies are focusing on research and development activity to improve the vascular stent products.  Major companies are focusing on the development of biodegradable stents to overcome the disadvantages of other available stents. Some major has adopted strategies of acquisitions and strategic alliances for the growth of the market.

Abbott Laboratories is one of the leading healthcare company headquartered in US. In June 2016, FDA has approved the Absorb bioresorbable Stent for heart. This stents is completely dissolve in the body and used in the treatment of heart complications. Company’s Esprit bioresorbable vascular scaffold is under clinical trials.


December, 2016 - Lombard Medical and MicroPort Scientific Corporation announced strategic partnership and investment agreement. This partnership allowed Lombard Medical to accelerate commercialization in global market with its two key products i.e Aorfix and Altura AAA. Aorfix, the only stent graft to hold global approvals to treat abdominal aortic aneurysms (AAA) with aortic neck angles up to 900, and Altura, a highly innovative stent graft that offers a simple and predictable treatment option for standard abdominal aortic aneurysms anatomy.

Boston Scientific Corporation is a global manufacturer and developer of medical devices headquartered in US. PROMUS Element Plus Stent, REBEL Stent System, SYNERGY Stent are some of the major products of the company. In 2014, company has launched Promus PREMIER Everolimus-eluting Platinum Chromium Coronary Stent System in Asia Pacific region. In 2015, worldwide sales of the company’s drug-eluting coronary stents were $1.074 billion as compared to $1.151 billion during 2014.

Medtronic is a medical device manufacturer headquartered in UK. It is the world's largest standalone medical technology development company. In 2015 company has develop Stent Graft System System for Endovascular Repair of Thoracoabdominal Aortic Aneurysms. Earlier company’s Resolute Drug-Eluting Stent has shown a very good performance in Diabetic Patients with Heart Disease. Medtronic market was increased by 7% in 2016 compared to 2015. Cook Medical is an US headquartered company involved in the manufacturing of the medical devices. Approach, Bird's Nest, Advance are some of the major product of the company.


Global Vascular Stents Market   - Regional Analysis
Geographically, the global vascular stents market is segmented into four regions. Of which North America commands market for vascular stents due to increasing obese population in North America is the major factor for the growth of the market. Beside this increasing people suffering from various cardiovascular diseases and lack of exercise also contributed in the growth of the market. Europe accounts second largest vascular stents market. While Asia Pacific is the fastest growing market due to rapid development in technology and a huge patient suffering from different vascular diseases. However, The Middle East and Africa has the lowest market for medical robotics because of limited development in medical field.
Posted by at No comments:
Labels: , , , ,

Cell Therapy Market - Industry Analysis on Top Key Players, Revenue Growth and Business Development Forecast 2017 – 2025

The global cell therapy market is due to grow at a CAGR of 10.6% during the forecast period of 2017 to 2023 according to Market Research Future's latest report on the subject. Cell therapy has emerged as a transformative field in biotechnology due to its use for the targeting of various diseases at a cellular level. The above-average growth expected by this market will primarily be due to the rapidly advancing healthcare sector and growing breakthrough research and development activities.



Cell therapy is finding a growing number of applications in healthcare and is often used in combination with gene therapy. Presently, applications of cell therapy include urinary problems, cancers, autoimmune disease, and infectious disease among several others. The growing prevalence of chronic and lifestyle diseases is an important driver for the cell therapy market. Cell therapy is also being developed in regenerative medicine which carries massive potential once it clears the research phase. Increasing geriatric population with health issues and technological advancements are some other factors governing market growth. government assistance for research and improvements being made in existing regulatory frameworks are expected to pave the way for future market opportunities.

However, it should be noted that the high cost of manufacturing at present and the lack of awareness or appropriate healthcare infrastructure are expected to challenge market growth.


Market Segmentation
The global cell therapy market is segmented on the basis of cell source, type, technology, application, end-user, and region. By type, the market is divided between autologous and allogeneic.

By technology, the market is segmented into viral vector technology, somatic cell technology, cell immortalization technology, genome editing technology, cell plasticity technology, and three-dimensional technology. The viral vector segment is sub-segmented into in-vivo gene modification of cells and ex-vivo gene modification of cells.
By cell source, the market is segmented to include bone marrow, umbilical cord blood-derived cells, adipose tissue, pluripotent stem cells (iPSCs), and neural stem cells.

By application, the market is segmented into cardiovascular, musculoskeletal, gastrointestinal, neurological, dermatology, oncology, wound & injuries, ocular, and others.

By end-user, the market is categorized into regenerative medicine centers, diagnostic centers, hospitals & clinics, research institutes and others.

The regional segmentation of the market divides it into the Americas, Europe, Asia Pacific and the Middle East & Africa.

Regional Analysis
The Americas with their inclusion of North America lead the market with the largest share due to the rising awareness regarding cell therapy in the region and the presence of an advanced healthcare sector. High healthcare expenditure, the presence of a large geriatric population and the growing demand for effective regenerative medicine are some of the important factors driving market growth. Europe accounts for the second largest regional segment due to the comparable growth pattern to that of the Americas. Moreover, the region has forward-thinking government policies which support research and development in the advancement of the healthcare sector.
The Asia Pacific accounts for the fastest growing region in the global market due to the presence of a massive patient pool and a rapidly developing healthcare sector. rising disposable incomes and urbanization in the region has increased the demand for advanced healthcare. Healthcare expenditure in the region is growing steadily and is expected to augment the cell therapy market in APAC.


Key Players
Prominent players in the global cell therapy market that have been included in MRFR's report are Cognate, ANTEROGEN.CO.,LTD., NuVasive, Inc., GlaxoSmithKline plc, Osiris, PHARMICELL, Pluristem, Genzyme Corporation, CELLECTIS, Advanced Tissue, Novartis AG, EUFETS GmbH, Cynata, BioNTech IMFS, JCR Pharmaceuticals Co., Ltd, Grupo Praxis, and MEDIPOST among others.
Latest Industry News
  • Novartis has received approval from the European commision for its CAR-T cell therapy.
  • After partnering with Regeneron, Bluebird is now looking out for more partnerships and collaborations to add to its capabilities as it works toward the advancement of cell therapy.
Posted by at No comments:
Labels: , , , , , , ,

Friday, March 15, 2019

The impact of Brexit on the U.S. pharmaceutical sector

With just over a month to go until the date of Britain’s exit from the EU, many industries are taking stock of what this could mean for business. None more so than the pharmaceutical industry, many businesses from which have invested heavily into the UK.
A new infographic from Alacrita has revealed the opinions of C-suite executives in the industry and their thoughts on whether the industry will be more or less likely to deal with Britain in a post-Brexit world.
On initial reading … it’s not great news.
Whilst the UK currently tops the tables of preferred EU countries to host clinical trials in, as well as the destination in which US companies wish to set up a European HQ in, 69 percent of US pharma execs said that Brexit would make the UK a less attractive destination for them to set up shop.
This could have a big effect on the amount of people the sector employs as well as the amount of money the industry brings to the UK.
Statistics show that the pharmaceutical sector currently employs around 67,000 people in the UK, with the wider life sciences sector employing around half a million.
The life sciences sector is also a major contributor to the UK economy. The ABPI calculated that in 2015, the life sciences sector contributed around £30.4bn in GVA (gross value added) and contributed £8.6bn in tax payments.
With these figures being so high, alterations to the UK’s suitability as a hub for these sort of projects is a gamble, and one that could lead to these figures falling over the next few years.
You can take a look at the infographic below to find out more about US pharma’s relationship with the EU and how this could be affected by Brexit.
Posted by at No comments:
Labels: ,

The Pharmaceutical Industry: Developing Cures for People

Our spotlight today is the pharmaceutical industry. This is the fourth part of this series which talks about the different characteristics of each industry and what investors should look out for. You can refer to the previous article on the retail industry here.
Note that the major pharmaceutical companies are located in three main countries — the U.S., Switzerland, and Japan — and some of the players are so huge that they are collectively known as “big pharma.”
Pharmaceutical companies form the bedrock of medical research as well as therapies that treat many dreaded diseases and illnesses such as diabetes, cancer, and tuberculosis, to name just a few. Without these companies and their large research and development (R&D) budgets, human beings would not be able to enjoy the quality of healthcare we enjoy now. But does this automatically make pharmaceutical companies good investments? Let’s take a dive into the industry.
R&D is a long, expensive, and laborious process
Investors need to understand that the R&D and drug approval process can be a long and laborious slog. There are four phases for clinical trials in order to not only test the efficacy of a drug but also gauge its side effects in a sampled population. Blind testing is done in phase 3 and may last several years, involving several hundred to several thousand people.
Assuming all trials are cleared and the drug still shows good promise, it still needs to be submitted to the U.S. Food and Drug Administration (FDA) for approval. The entire process from the start of phase 1 to FDA approval may take many years and cost millions of dollars.
Drug efficacy and sales potential are tough to model
For an investor who is thinking of projecting the revenue a successful drug can bring in, note that the efficacy of a drug when released to the general public and its sales potential are very tough variables to predict. There have been cases of drugs being approved that then led to adverse side effects in patients, resulting in lawsuits and the recall of said drug. The pharmaceutical company would, of course, have to write off millions of dollars of R&D spending if this were to happen.
A drug’s revenue potential may only be known a few years after it has been released, and it would depend on its acceptance by major healthcare institutions, pharmacies, and distribution channels. It would also depend on whether competitors are releasing a similar drug or compound that may divert sales away from the newly-launched drug.
Posted by at No comments:
Labels: , , ,
Subscribe to: Posts (Atom)